OncoLink Cancer Treatment and Resources

Prophylactic Surgery Decisions and Surveillance Practices One Year Following BRCA1/2 Testing

Caryn Lerman, Chanita Hughes, Roger Robert T. Croyle, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Reviewers: Li Liu, MD
Source: Preventive Medicine, Volume 31:75-80, (August) 2000

Précis: BRCA testing has low impact on screening compliance

Introduction

Germline BRCA1/2 mutations are associated with greatly increased risk of developing breast and ovarian cancers. Genetic testing has made it possible for some women to determine whether or not they escaped or inherited this mutation. One of the treatment options for women who carry BRCA1/2 mutations is prophylactic mastectomy and/or oophorectomy. This study evaluated screening compliance among identified mutation carriers.

Method

The investigators monitored 304 women in hereditary breast-ovarian cancer families who were offered BRCA1/2 testing. Of these women, 49 declined testing, 84 tested positive, 83 tested negative and the rest were lost to follow-up after 1 year. The investigators assessed prophylactic surgery and surveillance behavior one year following BRCA1/2 testing.

Results

  • One month after testing, 36% of carriers reported they were considering prophylactic mastectomy and 45% said they were considering prophylactic oophorectomy.
  • BRCA1/2 mutation carriers were significantly more likely than noncarriers to adopt the recommended mammography guidelines (68% vs. 44%).
  • 32% of carriers were not adherent at 1-year to mammographic follow-up guidelines and carriers? rates of mammography adherence were not significantly different from baseline.

Discussion

In this study, most women who were carriers of BRCA1 and BRCA2 mutations did not consider prophylactic mastectomy or oophorectomy to reduce their risk of breast and ovarian cancers, at least in the short term. Carriers also did not appear to improve their adherence to screening recommendations after learning their carrier status. Patient education and risk communication between patients and health care providers may help patients with their decision-making.

OncoLink I wish u knew...

Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS